Bextra, Valdyn (previously kudeq)(valdecoxib)
Bextra, Kudeq, Valdyn (valdecoxib) is a small molecule pharmaceutical. Valdecoxib was first approved as Bextra on 2001-11-16. It is used to treat dysmenorrhea, osteoarthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat dysmenorrhea, osteoarthritis, and rheumatoid arthritis. The pharmaceutical is active against prostaglandin G/H synthase 2. In addition, it is known to target carbonic anhydrase 12.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Valdecoxib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BEXTRA | G.D. Searle | N-021341 DISCN | 2001-11-16 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
31 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 5 | 3 | 1 | 10 |
| Postoperative pain | D010149 | — | G89.18 | — | — | 3 | 3 | 1 | 7 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 1 | — | 1 | 1 | 3 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | 1 | — | 1 |
| Rupture | D012421 | — | — | — | — | — | 1 | — | 1 |
| Emergence delirium | D000071257 | — | — | — | — | — | 1 | — | 1 |
| Hyperalgesia | D006930 | — | — | — | — | — | 1 | — | 1 |
| Sprains and strains | D013180 | — | — | — | — | — | 1 | — | 1 |
| Acute pain | D059787 | — | R52 | — | — | — | 1 | — | 1 |
| Dysmenorrhea | D004412 | HP_0100607 | N94.6 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | 2 | — | — | 2 |
| Pharyngitis | D010612 | — | R07.0 | — | 1 | 1 | — | — | 2 |
| Pancreatitis | D010195 | HP_0001733 | K85 | — | 1 | 1 | — | — | 1 |
| Endoscopic retrograde cholangiopancreatography | D002760 | — | — | — | 1 | 1 | — | — | 1 |
| Hallux valgus | D006215 | HP_0001822 | — | — | — | 1 | — | — | 1 |
| Laparoscopic cholecystectomy | D017081 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 1 | — | — | — | 1 |
| Postoperative complications | D011183 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Platelet aggregation | D010974 | GO_0070527 | — | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Valdecoxib |
| INN | valdecoxib |
| Description | Valdecoxib is a member of the class of isoxazoles that is isoxazole which is substituted at positions 3, 4 and 5 by phenyl, p-sulfamoylphenyl and methyl groups, respectively. A selective cyclooxygenase 2-inhibitor, it used as a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of arthritis from 2001 until 2005, when it was withdrawn following concerns of an associated increased risk of heart attack and stroke. It has a role as a non-steroidal anti-inflammatory drug, a cyclooxygenase 2 inhibitor, a non-narcotic analgesic, an antirheumatic drug and an antipyretic. It is a member of isoxazoles and a sulfonamide. |
| Classification | Small molecule |
| Drug class | cyclooxygenase-2 inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 181695-72-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL865 |
| ChEBI ID | 63634 |
| PubChem CID | 119607 |
| DrugBank | DB00580 |
| UNII ID | 2919279Q3W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CA2
CA2
Organism
Homo sapiens
Gene name
CA2
Gene synonyms
NCBI Gene ID
Protein name
carbonic anhydrase 2
Protein synonyms
CA-II, CAC, Carbonate dehydratase II, carbonic anhydrase B, Carbonic anhydrase C, Carbonic anhydrase II, carbonic dehydratase, Cyanamide hydratase CA2, epididymis luminal protein 76, epididymis secretory protein Li 282
Uniprot ID
Mouse ortholog
Car2 (12349)
carbonic anhydrase 2 (Q9DCY9)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Valdecoxib
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,000 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,894 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use